

1

2 **In vitro sensitivity of human parainfluenza 3 clinical isolates to ribavirin,**
3 **favipiravir and zanamivir.**

4

5 Authors: Anna Smielewska^{a,b}, Edward Emmott^{a,c}, Ian Goodfellow^a, Hamid Jalal^b.

6 ^aDivision of Virology, Department of Pathology, University of Cambridge,
7 Addenbrookes Hospital, Cambridge

8 ^bPHE – Public Health England Laboratory, Cambridge. Box 236, Cambridge
9 University Hospitals NHS Foundation Trust, Hills Road, Cambridge

10 ^cDepartment of Bioengineering, 332 Mugar Life Science Building, 360 Huntington
11 Ave, Northeastern University, Boston, MA, 02115-5000, USA

12

13

14 **# Address correspondence to: Anna Smielewska, aas31@cam.ac.uk**

15

16 **Word count: 2904**

17

18

19 **ABSTRACT**

20 **Background**

21 Human parainfluenza type 3 (HPIV3) is an important respiratory pathogen.
22 Although a number of potential therapeutic candidates exist, there is currently
23 no licensed therapy or vaccine. Ribavirin (RBV), favipiravir (FVP) and zanamivir
24 (ZNV) are inhibitors with proven activity against influenza and with potential
25 inhibitory activity against HPIV3 laboratory adapted strains *in vitro*.

26 **Objectives**

27 To evaluate RBV, FVP and ZNV as inhibitors of minimally passaged UK clinical
28 strains of HPIV3 as well as a laboratory adapted strain MK9 *in vitro*.

29 **Study Design**

30 The inhibitory action of RBV, FVP and ZNV was evaluated against nine minimally
31 passaged clinical strains and a laboratory adapted strain MK9 using plaque
32 reduction and growth curve inhibition in a cell culture model.

33 **Results**

34 Clinical isolates were found to be at least as susceptible as the laboratory
35 adapted strains to RBV and FVP and significantly more susceptible to ZNV.
36 However the inhibitory concentrations achieved by ZNV against clinical strains
37 remain prohibitively high *in vivo*.

38 **Conclusions:**

39 RBV, FVP and ZNV were found to be effective inhibitors of HPIV3 *in vitro*. The
40 lack of efficacy of RBV *in vivo* may be due to inability to reach required
41 therapeutic levels. FVP, on the other hand, is a good potential therapeutic agent
42 against HPIV3. Further studies using wild type clinical strains, as well as better

43 formulation and delivery mechanisms may improve the utility of these three
44 inhibitors.

45

46 Keywords: parainfluenza; ribavirin; favipiravir; zanamivir; clinical; therapy

BACKGROUND

Human parainfluenza viruses (HPIV) are a prominent cause of both upper (URTI) and lower (LRTI) respiratory tract infection with a broad spectrum of presentation (1–4). HPIV3 is recognised as a cause of serious morbidity and mortality in the immunocompromised, in particular among haematopoietic stem cell transplant (HSCT) patients(3, 5, 6). Immunity to HPIV3 is incomplete and re-infections occur throughout life. Currently there is no vaccine and no approved treatment for HPIV3, indicating a clear and urgent need for a potential therapeutic candidate.

Ribavirin is a nucleoside analogue with broad anti-viral activity *in vitro*(7, 8). It has been successfully used for treatment of hepatitis C and is licensed for treatment of respiratory syncytial virus (RSV), another member of the *Paramyxoviridae*, in young children. Although originally seen as a promising therapeutic candidate for treatment of HPIV3 in HSCT (9, 10) a recent meta analysis has shown that ribavirin had little or no effect on morbidity and mortality in patients with proven lower respiratory tract infection (LRTI) caused by HPIV3(6). This lack of therapeutic efficacy in patients necessitates a detailed evaluation of its inhibitory effect on clinical strains.

Favipiravir (T-705), a nucleoside analogue like ribavirin, is a selective and potent inhibitor of RNA dependent RNA polymerase activity and has been shown to be anti-viral by inducing lethal mutagenesis(11–13). *In vitro* it has demonstrated activity against a broad range of RNA viruses including *Paramyxoviridae*(12, 14,

15) including laboratory adapted strains of HPIV3.

Zanamivir is a neuraminidase inhibitor commonly prescribed for the treatment of influenza. The structure of the HPIV3 haemagglutinin neuraminidase binding pocket shows sufficient homology with that of the influenza neuraminidase, to suggest a potential high affinity for zanamivir(16). *In vitro* studies on tissue culture adapted strains have generally concluded that zanamivir has the potential to act as an inhibitor of HPIV3 albeit at therapeutically unachievable 50% maximum effective concentrations (EC₅₀) values(17). To date the potential of zanamivir as a therapeutic candidate for HPIV3 has yet to be evaluated systematically for clinical strains.

Overall, ribavirin, favipiravir and zanamivir have been evaluated *in vitro* against tissue culture adapted strains of HPIV3 and found to be effective to varying degrees.

OBJECTIVES

In this study we present an infectivity based *in vitro* model for the evaluation of potential therapeutic candidates for HPIV3 based on a tissue culture adapted reference strain and a panel of minimally passaged clinical strains. This represents a significant departure from previous *in vitro* models that have focused on significantly laboratory adapted strains.

95 **STUDY DESIGN**

96

97 For further details including molecular and plaque assay methods please see
98 supplementary methods.

99

100 ***Cells, virus and inhibitors.***

101 The PLC/PRF/5 human Alexander hepatoma cell line and the culture adapted
102 HPIV3 strain (MK9) were obtained from Public Health England (PHE) cultures.
103 Clinical strains were sourced from HPIV3 positive respiratory patient samples
104 collected between 2011 and 2015 by the PHE diagnostic laboratory
105 Addenbrooke's Hospital, Cambridge. Samples were anonymised and data
106 pertaining to patient demographics was collected where possible.

107 Ribavirin (RBV) and zanamivir (ZNV) were obtained from Sigma and favipiravir
108 (FVP) from Atomax.

109

110 ***Cell viability assay***

111 Cells in 96 well plates were either mock inoculated or inoculated with serial
112 dilutions of each inhibitor (ribavirin, favipiravir or zanamivir) starting with a
113 concentration of 1mM in eight biological repeats. Plates were then incubated at
114 33°C for 7 days and assayed with CellTiter-Blue® Cell Viability Assay (Promega)
115 as per the manufacturer's instructions.

116

117 ***Culture of HPIV3 clinical strains***

118 Cell monolayers were inoculated with clinical samples and incubated for 96
119 hours. Viral growth was evaluated by quantifying viral copy number in the

supernatant samples by qPCR on day zero and day four (see supplementary material). All samples demonstrating an increase of 10^3 or more in viral RNA were passaged again to prepare working stocks.

Subsequently an aliquot from each stock was tested on the diagnostic respiratory panel (PHE laboratory, Addenbrookes). Samples shown to be co-infected with other respiratory viruses were rejected. Nine strains with diverse plaque phenotype collected between 2011 and 2015 were subsequently selected for susceptibility work.

Plaque reduction assay

Cell monolayers were either mock inoculated or inoculated with the MK9 reference strain stock dilutions required to produce 20-100 plaques in each well. Inhibitors at required concentrations, or an equivalent volume of diluent were added to the overlay and the monolayers were incubated for 7 days, fixed and immunostained and plaque area was measured.

Growth inhibition

Cell monolayers were either mock inoculated or inoculated with laboratory strain (MK9) virus stock in triplicate. The inoculum was then removed and the monolayers were washed, covered with maintenance medium containing the inhibitors at required concentrations, or the equivalent volume of diluent, and incubated for 24 hours. Following the incubation period both the supernatant and the cells were harvested. Subsequently the concentration of released virus in the supernatant was determined by plaque titration. Viral RNA levels in infected cells was determined by qPCR and normalised to the total RNA in the sample.

145

146 ***Growth inhibition (clinical strains)***

147 Growth kinetic inhibition experiments were carried out on clinical strains as
148 above. Two concentrations of each inhibitor, corresponding to the 50% maximal
149 effective concentration (EC₅₀) and 90% maximal effective concentration (EC₉₀)
150 values, as interpolated from the dose response curve of infectious particle
151 reduction in the supernatant using reference strain MK9, were used. The EC₅₀
152 value for zanamivir was inferred from the dose response curve of the reduction
153 of viral copy number by qPCR and the higher concentration was taken as the
154 maximum concentration assayed, 1mM.

155

156 ***Binding inhibition with zanamivir***

157 Cell monolayers were inoculated with laboratory strain (MK9) in triplicate with
158 the required viral dilutions in maintenance medium with or without various
159 concentrations of zanamivir. The inoculum was then removed, the cells were
160 washed, covered with agarose overlay and incubated, fixed and immunostained.

161

162 ***Pre-incubation with zanamivir***

163 High viral titres were pre-incubated with different concentrations of zanamivir
164 or with equivalent volume of diluent (PBS) for 1 hour at 37°C. Mock controls
165 with UV inactivated virus with zanamivir, and zanamivir on its own were
166 included. Post incubation, the remaining infectivity in the sample was
167 determined by plaque assay. Each sample was diluted at least by a factor of 10⁴,
168 ensuring that any residual inhibitor effect was negligible.

169

170 **Binding inhibition and pre-incubation with zanamivir (clinical strains)**
171 Binding inhibition and pre-incubation with zanamivir was carried out on five
172 clinical strains that were shown to be significantly more susceptible to EC₅₀ ZNV
173 by growth inhibition (see above). For binding inhibition two concentrations of
174 the inhibitor were used. The lower concentration corresponded to the EC₅₀
175 interpolated from the dose response curve of binding inhibition using laboratory
176 strain MK9 and the higher was the maximum concentration used 1mM. For pre-
177 incubation with ZNV only the maximum concentration of 1mM was used.
178

179

180 **RESULTS**

181

182 **Isolation and cell culture growth of HPIV3 clinical isolates**

183 Residual clinical samples were collected between 2011 and 2015 from the PHE
184 diagnostic laboratory, Addenbrooke's hospital, Cambridge. 43 out of 407
185 samples were successfully grown at passage 1. Of these 3 samples were
186 identified as co-infected with another respiratory pathogen and were rejected
187 for subsequent studies. The other 40 samples underwent an additional passage
188 to produce working viral stocks. Nine clinical strains collected from different
189 years from diverse patient demographics and plaque phenotype were chosen for
190 further susceptibility testing (table 1).

191

192 Plaque area measurements, ranging from 0.3mm² to 1.47mm², reflect the diverse
193 plaque phenotype of the strains chosen (table1) The significant difference
194 between the plaque area of clinical strains and strain MK9 likely reflects the
195 culture adaptation of the laboratory strain.

196

197 The toxicity of all inhibitors was examined in PLC/PRF5 cells and no significant
198 reduction in cell viability was observed within the range of the concentrations
199 used for the experiments (data not shown).

200

201 **Impact of zanamivir, ribavirin and favipiravir on culture adapted HPIV3**

202

Figure 1: Laboratory adapted HPIV3 strain MK9 is sensitive to ribavirin and favipiravir but not zanamivir as measured by plaque area reduction.

Figure shows mean plaque area reduction as a percentage of the plaque area of untreated control \pm SEM for ribavirin (B), favipiravir (C) and zanamivir (D). Experimental design is shown in (A). All plaque areas were measured using Fiji. Curves were fitted using GraphPad Prism version 6.00 with $R^2 > 0.9$. Dashed lines represent the 95% confidence intervals. Each point represents three biological repeats.

To determine more accurately the effective concentration of each inhibitor against the lab adapted HPIV3 strain MK9, the EC_{50} was determined using plaque reduction assay where the inhibitor was present in the overlay. Ribavirin and favipiravir, but not zanamivir were shown to be effective inhibitors of HPIV3 strain MK9 by this method with an EC_{50} of 53.37 μ M for ribavirin and 137.8 μ M for favipiravir (figure 1B and C). This is consistent with the mode of action of zanamivir as a neuraminidase inhibitor affecting viral attachment and release(18, 19).

Figure 2: Growth of HPIV3 laboratory strain MK9 is effectively inhibited at 24 hours in the presence of ribavirin and favipiravir but not zanamivir.

Experimental design is shown in A. For each inhibitor concentration, the figure shows reduction of infectious units in the supernatant as a percentage of untreated control quantified by plaque titration (panels B, D and F) and the reduction in viral copy number normalized to the total RNA in the sample as a

percentage of untreated control by qPCR (panels C, E and G). Panels I and H summarize the reduction in infectious particle number (I) and viral copy number by qPCR (H) for all inhibitors. All points are averages of three biological replicates \pm SEM. All plaques were counted using Fiji. All curves were fitted using GraphPad Prism version 6 with $R^2 > 0.9$. Dashed lines represent 95% confidence intervals.

Subsequently the effect of each inhibitor on the growth kinetics of HPIV3 was evaluated. Ribavirin (figure 2B and C) and favipiravir (figure 2D and E) were observed to be effective inhibitors of HPIV3 (figure 2A). Due to the mutagenic nature of favipiravir an EC_{90} was not achieved with this inhibitor when measured by the reduction in genome copy number in cells (figure 2E)). Zanamivir appeared to be the least effective of these inhibitors, achieving a maximum of 10% inhibition of released virus and approximately 70% reduction in genome copy number in cells at maximum concentration assayed (1mM). The EC_{50} of zanamivir (200 μ M) for subsequent work was calculated from the dose response curve fitted to the reduction in genome copy number (figure 2G).

Zanamivir inhibits HPIV3 at the level of virus binding.

Figure 3: Zanamivir inhibits HPIV3 at the level of virus binding.

Experimental design is shown in A (binding inhibition) and C (pre-incubation). The figure shows the effect on laboratory strain MK9 when zanamivir is present during inoculation (B) and when pre-incubated with zanamivir (D) to exclude the possibility of direct effects on virus particles. Panel D (pre-incubation) shows

no significant effect on viral replication. In both cases the figure shows the reduction of the number of infectious units as a percentage of untreated control by plaque titration +/- SEM. All plaques were counted using Fiji. All curves were fitted using GraphPad Prism version 6.00 with $R^2 > 0.9$. Dashed lines represent 95% confidence intervals.

The ability of zanamivir to act as a binding inhibitor of HPIV3 and its effect on the viral particle itself was assessed by adding the inhibitor during the inoculation stage and pre-incubating the virus with it respectively. Zanamivir has been shown to inhibit HPIV3 at a higher concentration (EC_{50} of $295\mu M$) when added during the inoculation stage (figure 3). Pre-incubation of HPIV3 with zanamivir has had no effect on the reduction of infectious particle number, confirming that zanamivir has no direct anti-viral activity.

Clinical strains of HPIV3 are susceptible to ribavirin, favipiravir and zanamivir

Figure 4: Clinical strains of HPIV3 are susceptible to ribavirin, favipiravir and zanamivir. Experimental design is shown in (A). For each clinical strain the figure shows the reduction of infectious units in the supernatant by plaque titration as a percentage of the untreated control +/- SEM. 9 clinical strains and strain MK9 were inoculated at low MOI and incubated for 24 hours in triplicate with two concentrations of each inhibitor (EC_{50} and EC_{90} values interpolated, where possible, from dose response curves using reference strain MK9 (figure 2E)). For zanamivir the EC_{50} value was interpolated from the dose response

curve reduction in viral copy number (figure 2G) and the higher concentration was taken to be the maximum used experimentally (1mM) as EC₉₀ was not achieved with this inhibitor.

Subsequently the EC₅₀ of all three inhibitors and the EC₉₀ of ribavirin and favipiravir, as well as the highest concentration assays (1mM) of zanamivir, were assayed against clinical strains of HPIV3. All clinical strains were shown to be sensitive to the three inhibitors (figure 4) with the majority of the clinical strains typically being at least as susceptible to the drugs as the reference strain (table 2). Although laboratory strain MK9 was shown to be resistant to zanamivir, 5 out of 9 clinical strains at 200µM, all clinical strains at 1mM were shown to be sensitive to this inhibitor.

Clinical strains of HPIV3 are susceptible to zanamivir at the level of virus binding.

Figure 5 Clinical strains are susceptible to zanamivir at the level of virus binding

Experimental design is shown in (A). For each clinical strain the figure shows the reduction in infectious units by plaque titration as a percentage of the untreated control +/- SEM. The lower concentration (EC₅₀ value) was interpolated from the dose response curve using reference strain MK9 (figure 3B) the higher concentration was taken to be the maximum used experimentally (1mM). All plaques were counted using Fiji.

303

304 In order to investigate further the effect of ZNV on HPIV3 during binding, the
305 above experiment was repeated with the five clinical strains that were
306 significantly susceptible to ZNV at 200 μ M. All the clinical strains were shown to
307 be as sensitive to ZNV as reference strain MK9 by this method (figure 5).
308 Similarly to the laboratory strain, pre-incubation with ZNV was shown to have
309 no effect on the reduction in infectious particle number of these clinical strains
310 (data not shown).

311

DISCUSSION

In this study ribavirin, favipiravir and zanamivir have been evaluated as potential inhibitors of HPIV3 in both a laboratory adapted strain and nine distinct minimally passaged clinical strains obtained between the years 2011-2015. The clinical strains selected for this study originated from a diverse population of patients and can therefore be considered representative of the population covered by the PHE diagnostic laboratory Addenbrookes Hospital, Cambridge.

Our results confirmed that ribavirin is an effective inhibitor of HPIV3 *in vitro* both by plaque reduction and by growth inhibition assays (figures 1 and 2). An approximately 4-fold decrease in EC₅₀ value against laboratory strain MK9 between the one obtained by plaque titration (53.37µM) (figure 1) and by growth kinetics inhibition (15.14µM) (figure 2) was noted. This discrepancy was likely due to differences in methodology including the stability of the inhibitor in the overlay (7 days vs 24 hour incubation), the timing of data collection and viral spread confined to cell to cell fusion in plaque assays. Clinical strains have been shown to be at least as susceptible to ribavirin as the laboratory strain with a potential lower EC₅₀ for clinical strains (figure 4).

These figures are compatible with ribavirin bioavailability studies that demonstrate an average level of 8.19µM, with a potential correlation with haemoglobin drop above 4µM(20) during hepatitis C therapy. In the case of RSV treatment(21, 22), where ribavirin is delivered by aerosol, plasma levels

achieved are significantly less than the EC₅₀ observed in this study and range from 0.76µM to 6.8µM, depending on length of delivery(23) . Unfortunately neither study provides data on concentrations in the respiratory tract. As such, although ribavirin remains an effective inhibitor of HPIV3 *in vitro*, further optimization of drug design or combination therapy is required to yield a regimen capable of delivering therapeutically useful concentrations at the site of infection.

Favipiravir is a nucleoside analogue with a broad spectrum of action, and has been shown to be effective against other RNA viruses such as influenza, ebola and laboratory adapted parainfluenza strains *in vitro*(14, 15, 24, 25). Given the similarities in the RNA dependent RNA polymerase, it is a promising inhibitor of HPIV3. Overall we observed that favipiravir is an effective inhibitor of HPIV3 both by plaque reduction and growth kinetics inhibition assay in the current model (figures 1 and 2), with 8 out of 9 clinical strains tested being at least as sensitive to favipiravir as the laboratory strain MK9 (figure 4). In this study an EC₅₀ of approximately 138µM was determined for HPIV3 by both plaque reduction and growth kinetics inhibition (figure 2).

As favipiravir is a relatively novel therapeutic drug, very limited *in vivo* data on plasma concentrations achieved in humans is available(15), although a number of *in vivo* studies using small rodent models(14, 26, 27) and well as non-human primates(28) have been conducted. Recently released data from the JIKI trial (Efficacy of favipiravir against ebola trial) quoted trough plasma levels of 293µM on day 2 and 165µM on day 4 of treatment(25). This exceeds the EC₅₀ and EC₉₀

values quoted in literature(14, 27) and observed in this study. Although encouraging, this should be interpreted with caution, as no data on favipiravir concentration in respiratory secretions and in the lungs is currently available.

In this study we have observed ZNV to be ineffective against the laboratory strain by two assays (figures 1 and 2), all of the clinical strains demonstrated at least a 50% reduction in infectious particle number in the supernatant at 1mM and 2 out of 9 strains tested demonstrated ~ 50% inhibition at 200µM (figure 4). We have also demonstrated that zanamivir acts as a binding inhibitor of HPIV3 at EC₅₀ of 295µM, although an EC₉₀ was not achieved below 1mM (figure 3). No difference was observed between the sensitivity to ZNV in its capacity as a binding inhibitor by the laboratory strain MK9 and the clinical strains tested (figure 5).

This is consistent with previous data that indicates that the HN protein of HPIV3 contains two binding sites and is responsible for the binding, fusion triggering and release of the new viral particle(29). In its capacity as a binding inhibitor, ZNV is known to bind to site I with a non-specific distortion of site II(29). The fusion and release processes, on the other hand have been linked to binding site II (29, 30). Moreover a specific mutation (N556D) at binding site II has been linked to culture adaptation and has been shown to confer a 5-fold decrease in neuraminidase activity between a wild type strain and significantly culture adapted one (31). This has been linked to a more robust interaction with the cell receptor(32) and a larger plaque phenotype (table 1) in significantly culture adapted strains(31). It is of note that the reference strain MK9 contains that

mutation and hence the reduced neuraminidase activity whereas the clinical strains used in this study do not. This agrees with the results of this study, where clinical strains have been shown to be more susceptible to ZNV than laboratory strain MK9 by growth inhibition but not at the level of binding.

Although this data is encouraging, the inhibitory concentrations achieved in this study still exceed zanamivir levels in nasal secretions (between 200µM and 300µM) achieved during influenza treatment(33). Nonetheless the observed susceptibility of clinical strains to zanamivir confirms the importance of conducting further studies in this area on clinical strains with minimal culture adaptation.

In this study we have presented an *in vitro* infectivity based model for evaluating HPIV3 susceptibility to potential therapeutic candidates using a tissue culture adapted reference strain MK9 and 9 diverse clinical strains. A necessary limiting factor in methodologies that involve immortalized cell culture is the reliance on viruses that are able to grow in this environment. A markedly larger plaque phenotype is associated with significant culture adaptation as demonstrated by the laboratory strain(31). Within these constraints, and as all clinical samples have been minimally and equally passaged in cell culture, the diversity in plaque size is an indication of diversity of phenotype of the clinical samples used in this study. There is good evidence that heavily laboratory adapted HPIV3 strains are non-representative of the currently circulating clinical strains(30, 31). Despite recent advances in human airway epithelial (HAE) culture systems(31), these are often not suitable when large volume, high titre stocks are required for

412 subsequent downstream analysis. We have found ribavirin and favipiravir, but
413 not zanamivir to be effective inhibitors of both the tissue culture adapted strain
414 and clinical strains of HPIV3. Overall clinical strains were significantly more
415 susceptible to zanamivir. Further work on clinical circulating strains, optimized
416 methods of delivery and targeted clinical trials are required to formulate
417 treatment for this important pathogen.

418

419

420 COMPETING INTERESTS

421 None declared

422

423

424 FUNDING INFORMATION

425 This work was supported by Public Health England (PHE) PhD studentship fund

426 2013. The funders had no role in study design, data collection and interpretation,

427 or the decision to submit the work for publication.

428

429

REFERENCES

1. Mao N, Ji Y, Xie Z, Wang H, Wang H, An J, Zhang X, Zhang Y, Zhu Z, Cui A, Xu S, Shen K, Liu C, Yang W, Xu W. 2012. Human parainfluenza virus-associated respiratory tract infection among children and genetic analysis of HPIV-3 strains in Beijing, China. *PLoS One* 7:e43893.
2. Lewandowska-Polak A, Brauncajs M, Paradowska E, Jarzębska M, Kurowski M, Moskwa S, Leśnikowski ZJ, Kowalski ML. 2015. Human parainfluenza virus type 3 (HPIV3) induces production of IFN γ and RANTES in human nasal epithelial cells (HNECs). *J Inflamm (Lond)* 12:16.
3. Shah DP, Shah PK, Azzi JM, Chemaly RF. 2016. Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review. *Cancer Lett* 370:358–364.
4. Liu W-K, Liu Q, Chen D-H, Liang H-X, Chen X-K, Huang W-B, Qin S, Yang Z-F, Zhou R. 2013. Epidemiology and clinical presentation of the four human parainfluenza virus types. *BMC Infect Dis* 13:28.
5. Nichols WG. 2001. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. *Blood* 98:573–578.
6. Seo S, Xie H, Campbell AP, Kuypers JM, Leisenring WM, Englund JA, Boeckh M. 2014. Parainfluenza Virus Lower Respiratory Tract Disease After Hematopoietic Cell Transplant: Viral Detection in the Lung Predicts Outcome. *Clin Infect Dis* 58:1357–1368.
7. Crotty S, Cameron C, Andino R. 2002. Ribavirin's antiviral mechanism of action: Lethal mutagenesis? *J Mol Med* 80:86–95.

- 455 8. Leyssen P, Balzarini J, De Clercq E, Neyts J. 2005. The Predominant
456 Mechanism by Which Ribavirin Exerts Its Antiviral Activity In Vitro against
457 Flaviviruses and Paramyxoviruses Is Mediated by Inhibition of IMP
458 Dehydrogenase. *J Virol* 79:1943–1947.
- 459 9. Lewis VA, Champlin R, Englund J, Couch R, Goodrich JM, Rolston K,
460 Przepiorka D, Mirza NQ, Yousuf HM, Luna M, Bodey GP, Whimbey E. 1996.
461 Respiratory disease due to parainfluenza virus in adult bone marrow
462 transplant recipients. *Clin Infect Dis* 23:1033–7.
- 463 10. Chakrabarti S, Collingham KEEE, Holder K, Oyaide S, Pillay D, Milligan
464 DWWW. 2000. Parainfluenza virus type 3 infections in hematopoietic stem
465 cell transplant recipients: response to ribavirin therapy. *Clin Infect Dis*
466 31:1516–1518.
- 467 11. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. 2013.
468 Favipiravir (T-705), a novel viral RNA polymerase inhibitor. *Antiviral Res*
469 100:446–454.
- 470 12. Vanderlinden E, Vrancken B, Houdt J Van, Rajwanshi VK, Gillemot S, Andrei
471 G, Lemey P, Naesens L. 2016. Distinct Effects of T-705 (Favipiravir) and
472 ribavirin on influenza virus replication and Viral RNA Synthesis.
473 *Antimicrob Agents Chemother* 60:6679–6691.
- 474 13. Arias A, Thorne L, Goodfellow I. 2014. Favipiravir elicits antiviral
475 mutagenesis during virus replication in vivo. *Elife* 3:e03679.
- 476 14. Jochmans D, Van Nieuwkoop S, Smits SL, Neyts J, Fouchier RAM, Van Den
477 Hoogen BG. 2016. Antiviral activity of favipiravir (T-705) against a broad
478 range of paramyxoviruses in vitro and against human metapneumovirus in
479 hamsters. *Antimicrob Agents Chemother* 60:4620–4629.

- 480 15. Madelain V, Nguyen THT, Olivo A, de Lamballerie X, Guedj J, Taburet AM,
481 Mentré F. 2016. Ebola Virus Infection: Review of the Pharmacokinetic and
482 Pharmacodynamic Properties of Drugs Considered for Testing in Human
483 Efficacy Trials. Clin Pharmacokinet.
- 484 16. Lawrence MC, Borg NA, Streltsov VA, Pilling PA, Epa VC, Varghese JN,
485 McKimm-Breschkin JL, Colman PM. 2004. Structure of the Haemagglutinin-
486 neuraminidase from Human Parainfluenza Virus Type III. J Mol Biol
487 335:1343–1357.
- 488 17. Greengard O, Poltoratskaia N, Leikina E, Zimmerberg J, Moscona A. 2000.
489 The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion
490 mediated by human parainfluenza virus and influenza virus HA. J Virol
491 74:11108–11114.
- 492 18. Lamb R a., Paterson RG, Jardetzky TS. 2006. Paramyxovirus membrane
493 fusion: Lessons from the F and HN atomic structures. Virology 344:30–37.
- 494 19. Porotto M, Greengard O, Poltoratskaia N, Horga M a, Moscona a. 2001.
495 Human parainfluenza virus type 3 HN-receptor interaction: effect of 4-
496 guanidino-Neu5Ac2en on a neuraminidase-deficient variant. J Virol
497 75:7481–7488.
- 498 20. Karin Jorga C, Hoffmann-La Roche F, Wade JR, Snoeck E, Duff F, Lamb M,
499 Jorga K. 2006. Pharmacokinetics of ribavirin in patients with hepatitis C
500 virus. Br J Clin Pharmacol Br J Clin Pharmacol 626:710–714.
- 501 21. Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S, Ten Eyck LG,
502 Hall WJ. 1983. Aerosolized Ribavirin Treatment of Infants with
503 Respiratory Syncytial Viral Infection. N Engl J Med 308:1443–1447.
- 504 22. Smith DW, Frankel LR, Mathers LH, Tang ATS, Ariagno RL, Prober CG.

1991. A Controlled Trial of Aerosolized Ribavirin in Infants Receiving Mechanical Ventilation for Severe Respiratory Syncytial Virus Infection. *N Engl J Med* 325:24–29.

23. VIRAZOLE® (Ribavirin for Inhalation Solution, USP) [package insert], ICN Pharmaceuticals, Inc, Costa Mesa, California, USA, 2000.

24. Mentré F, Taburet A-M, Guedj J, Anglaret X, Keïta S, de Lamballerie X, Malvy D. 2015. Dose regimen of favipiravir for Ebola virus disease. *Lancet Infect Dis* 15:150–1.

25. Nguyen THT, Guedj J, Anglaret X, Laouénan C, Madelain V, Taburet A-M, Baize S, Sissoko D, Pastorino B, Rodallec A, Piorkowski G, Carazo S, Conde MN, Gala J-L, Bore JA, Carbonnelle C, Jacquot F, Raoul H, Malvy D, de Lamballerie X, Mentré F, group on behalf of the J study. 2017. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. *PLoS Negl Trop Dis* 11:e0005389.

26. Mendenhall M, Russell A, Smee DF, Hall JO, Skirpstunas R, Furuta Y, Gowen BB. 2011. Effective Oral Favipiravir (T-705) Therapy Initiated after the Onset of Clinical Disease in a Model of Arenavirus Hemorrhagic Fever. *PLoS Negl Trop Dis* 5:e1342.

27. Gowen BB, Sefing EJ, Westover JB, Smee DF, Hagloch J, Furuta Y, Hall JO. 2015. Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. *Antiviral Res* 121:132–137.

28. Madelain V, Guedj J, Mentré F, Nguyen THT, Jacquot F, Oestereich L, Kadota T, Yamada K, Taburet AM, De Lamballerie X, Raoul H. 2017. Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy

530 studies of hemorrhagic fever viruses. Antimicrob Agents Chemother
531 61:e01305-16.

532 29. Porotto M, Fornabaio M, Kellogg GE, Moscona A. 2007. A second receptor
533 binding site on human parainfluenza virus type 3 hemagglutinin-
534 neuraminidase contributes to activation of the fusion mechanism. J Virol
535 81:3216–28.

536 30. Palmer SG, Porotto M, Palermo LM, Cunha LF, Greengard O, Moscona A.
537 2012. Adaptation of human parainfluenza virus to airway epithelium
538 reveals fusion properties required for growth in host tissue. MBio
539 3:e00137-12-.

540 31. Palermo LM, Uppal M, Skrabanek L, Zumbo P, Germer S, Toussaint NC,
541 Rima BK, Huey D, Niewiesk S, Porotto M, Moscona A. 2016. Features of
542 Circulating Parainfluenza Virus Required for Growth in Human Airway.
543 MBio 7:e00235.

544 32. Murrell M, Porotto M, Weber T, Greengard O, Moscona A. 2003. Mutations
545 in human parainfluenza virus type 3 hemagglutinin-neuraminidase
546 causing increased receptor binding activity and resistance to the transition
547 state sialic acid analog 4-GU-DANA (Zanamivir). J Virol 77:309–317.

548 33. Cass LM, Efthymiopoulos C, Bye A. 1999. Pharmacokinetics of zanamivir
549 after intravenous, oral, inhaled or intranasal administration to healthy
550 volunteers. Clin Pharmacokinet 36 Suppl 1:1–11.

551
552
553
554

sample				patient			
Lab ID	Date collected	source	Plaque area mm ² +/- SEM	sex	age	location	In/out patient
14	Nov-14	URT swab	0.30+/- 0.04	F	1 year	Basildon hospital	in
16	May-14	URT swab	0.33+/- 0.03	M	50 years	Addenbrooke's hospital	in
65	Jun-11	URT swab	1.47+/- 0.11	F	54 years	Addenbrooke's hospital	in
82	Jul-11	URT swab	1.46+/- 0.16	M	2 months	Harlow hospital	in
113	Jul-12	URT swab	0.94+/- 0.05	M	42 years	Addenbrooke's hospital	in
129	Feb-13	Tracheal aspirate	0.92+/- 0.04	F	4 years	Frimley Park hospital	in/ICU
153	Apr-13	NPA	0.83+/- 0.03	F	12 years	Frimley Park hospital	in
180	May-13	NPA	0.57+/- 0.02	F	3 months	Addenbrooke's hospital	out
362	Mar-15	URT swab	0.59+/- 0.06	F	80 years	Essex nursing home	out
LS MK9	n/a	n/a	3.96+/- 0.45	n/a	n/a	n/a	n/a

Table 1: Clinical strains selected for susceptibility testing. Clinical strains

were collected between 2011 and 2015, all originated from the upper airway of patients with 4/9 from Addenbrooke's Hospital, Cambridge. Plaque area for the clinical strains averaged at 0.82mm² +/- 0.03 (SEM) with a range between 0.3 mm² and 1.47mm², with strains from 2011 (65 and 82), demonstrating a comparatively large plaque phenotype. Strain MK9 is a laboratory adapted strain obtained from PHE cell culture collections.

drug	concentration	average percentage of untreated control (PFUs/ml) +/- SEM		number of clinical strains with significant deviation from the laboratory strain (FDR 1%)		
		lab strain	clinical strains	less sensitive	more sensitive	no difference
ribavirin	RBVIC50	47.94+/- 5.97	21.5+/-2.08	0 (0%)	8 (89%)	1 (11%)
	RBVIC90	9.12+/-0.76	5.15+/-0.78	1 (11%)	4 (44.5%)	4 (44.5%)
favipiravir	FVP IC50	47.95+/- 1.37	39.77+/-3.69	1 (11%)	4 (44.5%)	4 (44.5%)
	FVP IC90	13.56+/- 0.23	14.03+/-1.73	1 (11%)	3 (33%)	5 (56%)
zanamivir	ZNV 200µM	98.63+/- 4.11	75.86+/-3.21	0 (0%)	5 (55.5%)	4 (44.5%)
	ZNV 1mM	90.41+/- 4.75	25.94+/-3.72	0 (0%)	9 (100%)	0 (0%)

569

570 **Table 2: Clinical strain susceptibility to favipiravir, ribavirin and zanamivir**

571 Average EC₅₀ and EC₉₀ values for each clinical strain and for the laboratory strain

572 MK9 (PHE cultures) determined by plaque titration of supernatant after 24 hour

573 incubation (figure 4) are summarized. A summary of how many clinical strains

574 were more, less or equally susceptible to each inhibitor is included for each

575 inhibitory concentration. All plaques were counted using Fiji.

576

577


578

579


580

Figure 1


A. Experimental time line



B. Ribavirin



C. Favipiravir



D. Zanamivir






Figure 2


A. Experimental time line




B. Ribavirin PFUs/ml reduction




C. Ribavirin viral copy number reduction




D. Favipiravir PFUs/ml reduction




E. Favipiravir viral copy number reduction




F. Zanamivir PFUs/ml reduction



G. Zanamivir viral copy number reduction



H. PFUs/ml reduction (all inhibitors)



I. Viral copy number reduction (all inhibitors)






Figure 3


A. Experimental timeline - binding inhibition



C. Experimental timeline - pre-incubation



B. Binding inhibition



D. Pre-incubation




Figure 4






Figure 5

A. Experimental timeline - binding inhibition



B. Zanamivir - binding inhibition (clinical strains)



SUPPLEMENTARY METHODS

Cells

HPIV3 has been cultured previously in numerous cell lines including, among others: CV-1, 293T, Hep2, MDCK and Vero(1, 2). In this case the PLC/PRF/5 cell line was chosen as it was previously used for tissue culture based diagnosis of respiratory viruses in the laboratory that has supplied the clinical samples for this study. More importantly, it was judged, that as this line was suitable for diagnostics, it would be suitable for isolation of clinical strains.

The cell line was maintained in Dulbecco Modified Eagle Medium (DMEM) high glucose medium supplemented with 10% fetal bovine serum (FBS), penicillin (100 SI units/ml), streptomycin (100µg/ml) and 2mM L-glutamine at 37°C in 5% CO₂.

Culture of HPIV3 clinical strains

Cell monolayers were set up at 70% confluence in T25 flasks and each monolayer was inoculated with 20µl clinical sample in 200µl maintenance medium (high glucose DMEM with 1% fetal bovine serum (FBS) and 2mM L-glutamine) supplemented with penicillin 100U/ml, streptomycin 100µg/ml, gentamicin 50µg/ml, ceftazidime 50µg/ml, vancomycin 50µg/ml and fungizone (amphotericin B) 5µg/ml to minimize bacterial and fungal out growth. Infections were carried out at 37°C for 2 hours. The inoculum was then removed, the cells washed twice in PBS, covered with maintenance medium as above and incubated for 4 days at 33°C in 5% CO₂. Supernatant samples of 50µl were collected on day zero and day four. Viral growth was evaluated by quantifying viral copy number

in the supernatant samples by qPCR (see protocol below).
Subsequently an aliquot from each stock was tested on the diagnostic respiratory panel (PHE laboratory, Addenbrookes) including the following common viruses: influenza A and B, RSV, enterovirus, rhinovirus, HMPV, adenovirus and HPIV1, 2, 3 and 4.

Statistical analysis

All statistical analysis was carried out in GraphPad Prism version 6.00 for Mac OS X, GraphPad Software, La Jolla California USA, www.graphpad.com. Linear regressions from the standard curve for qPCR were fitted using the linear regression model. Dose response curves for drug inhibition assays were fitted using the 4 parameter logistic (4PL) fit. Curves with $R^2 > 0.9$ and a $p < 0.05$ for replicates test for lack of fit were accepted as adequate models.

qPCR

Total RNA from samples was extracted using the GenElute Mammalian Total RNA Miniprep kit (Sigma) according to the manufacturer's guidelines. This was amplified on the ViiA7 Real Time PCR system (Applied Biosystems) using a qPCR protocol obtained and modified from the standard operating procedure (SOP) for HPIV3 typing used by the PHE diagnostic laboratory, Addenbrookes Hospital, Cambridge. The primers and the taqman probe used were: forward 5'-GCTCCTTTYATCTGTATCCTCAGAGATCC-3', reverse 5'-TGATCTTCCCGTCACATACTGTTGCATG-3', probe 5'-FAM-ATAGTTGCCTGGTGCGAA-TAMRA-3'. The cycling conditions used were: hold at 50°C for 30min, hold at 95°C for 2 min, followed by 45 cycles while acquiring

51 fluorescence data through 95°C for 15s and 60°C for 60s. An amplicon from the
52 diagnostic assay positive control was obtained and cloned by TA cloning using
53 the PureYield™ Plasmid Midiprep System (Promega). The sequence of the
54 amplicon aligned to 138bp of the nucleocapsid gene of HPIV3 (nucleotides 981-
55 1118). Ten fold serial dilutions of the plasmid were subsequently used to
56 establish a standard curve. Linear regression of the standard curve for genome
57 copy number quantification was fitted using GraphPad Prism version 6.00.

58 ***Plaque assay***

59 Monolayers at 80-90% confluence (approximately $0.96 - 1.08 \times 10^6$ cells/well)
60 were set up in 6 well plates and infected with serial dilutions of virus stock
61 (500µl/well). Infections were carried out in maintenance medium (high glucose
62 DMEM supplemented with 1% fetal bovine serum (FBS), penicillin (100 SI
63 units/ml), streptomycin (100µg/ml) and 2mM L-glutamine) at 37°C for 2 hours.
64 The inoculum was then removed and the monolayers washed twice in PBS. A 1%
65 agarose overlay with 50% maintenance medium was applied to the infected
66 monolayer. The plates were then incubated inverted at 33°C in 5% CO₂ for 7
67 days. Subsequently they were fixed with 2% formaldehyde in PBS, the agarose
68 plugs were removed and the monolayers were washed three times in PBS prior
69 to immunostaining. Each titration was performed in triplicate.

70 The infected cells were stained with a mixture of three rabbit polyclonal anti-F
71 HPIV3 antibodies at 1:5000 dilution in PBS containing 5% FBS at room
72 temperature for 1 hour (500µl/well). The antibodies were raised against the
73 following epitopes NQESNENTDPRTERF (amino acids 96-110),
74 NRVDQNDKPYVLTK (amino acids 525-539), and KEWIRRSNQKLD SIG (amino

acids 471-485) of the F protein. The cells were then washed three times with PBS, leaving each wash on for 5 min, and subsequently incubated with an anti-rabbit HRP conjugated secondary antibody at 1:1000 in PBS containing 5% FBS at room temperature for 1 hour (500µl/well). The cells were washed 5 times in PBS and reacted with True Blue Peroxidase substrate (SeraCare) (500µl/well) for 20min at room temperature. The plaques were scanned and subsequently identified and measured using the Fiji analyze particles module(3).

1. Palmer SG, Porotto M, Palermo LM, Cunha LF, Greengard O, Moscona A. 2012. Adaptation of human parainfluenza virus to airway epithelium reveals fusion properties required for growth in host tissue. MBio 3:e00137-12-.
2. Jochmans D, Van Nieuwkoop S, Smits SL, Neyts J, Fouchier RAM, Van Den Hoogen BG. 2016. Antiviral activity of favipiravir (T-705) against a broad range of paramyxoviruses in vitro and against human metapneumovirus in hamsters. Antimicrob Agents Chemother 60:4620–4629.
3. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. 2012. Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–682.